Trial · NCT00622284
Results by group58
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 58
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| HbA1c Change From Baseline at Week 52 | Linagliptin | -0.36 | Standard Error 0.03 | Percent | |
| HbA1c Change From Baseline at Week 52 | Glimepiride | -0.57 | Standard Error 0.03 | Percent | |
| HbA1c Change From Baseline at Week 104 | Linagliptin | -0.16 | Standard Error 0.03 | Percent | |
| HbA1c Change From Baseline at Week 104 | Glimepiride | -0.36 | Standard Error 0.03 | Percent | |
| Body Weight Change From Baseline at Week 52 | Linagliptin | -1.12 | Standard Error 0.13 | kg | |
| Body Weight Change From Baseline at Week 52 | Glimepiride | 1.38 | Standard Error 0.14 | kg | |
| Body Weight Change From Baseline at Week 104 | Linagliptin | -1.39 | Standard Error 0.16 | kg | |
| Body Weight Change From Baseline at Week 104 | Glimepiride | 1.29 | Standard Error 0.16 | kg | |
| Incidence of Hypoglycaemic Events up to 52 Weeks | Linagliptin | 41 | Patients | ||
| Incidence of Hypoglycaemic Events up to 52 Weeks | Glimepiride | 249 | Patients | ||
| Incidence of Hypoglycaemic Events up to 104 Weeks | Linagliptin | 58 | Patients | ||
| Incidence of Hypoglycaemic Events up to 104 Weeks | Glimepiride | 280 | Patients | ||
| Fasting Plasma Glucose (FPG) Change From Baseline at Week 52 | Linagliptin | -8.40 | Standard Error 1.25 | mg/dL | |
| Fasting Plasma Glucose (FPG) Change From Baseline at Week 52 | Glimepiride | -15.24 | Standard Error 1.26 | mg/dL | |
| Fasting Plasma Glucose (FPG) Change From Baseline at Week 104 | Linagliptin | -2.34 | Standard Error 1.46 | mg/dL | |
| Fasting Plasma Glucose (FPG) Change From Baseline at Week 104 | Glimepiride | -8.72 | Standard Error 1.47 | mg/dL | |
| Percentage of Patients With HbA1c <7.0% at Week 52 | Linagliptin | 29.6 | Percentage of patients | ||
| Percentage of Patients With HbA1c <7.0% at Week 52 | Glimepiride | 38.9 | Percentage of patients | ||
| Percentage of Patients With HbA1c <7.0% at Week 104 | Linagliptin | 21.0 | Percentage of patients | ||
| Percentage of Patients With HbA1c <7.0% at Week 104 | Glimepiride | 28.3 | Percentage of patients |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00622284/results